3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Endometrial Neoplasms
2
Stomach Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lung Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
23
Paclitaxel
14
Cyclophosphamide
13
Carboplatin
12
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
9
fludarabine
8
Nivolumab
7
Leucovorin
7
Gemcitabine
7
Fluorouracil
7
Doxorubicin
7
aldesleukin
6
Oxaliplatin
6
Cisplatin
6
liposomal doxorubicin
5
Topotecan
5
Taxes
5
Irinotecan
5
Interleukin-2
5
olaparib
4
atezolizumab
4
Hyperthermic Intraperitoneal Chemotherapy
4
Drug Therapy
4
seribantumab
3
fludarabine phosphate
3
durvalumab
3
dostarlimab
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
pemigatinib
×
Gynecologic
×
Clear all
NCT04463771
2025-12-10
POD1UM-204
Incyte Corporation
Phase 2
Active not recruiting
206 enrolled